A study of R435(Bevacizmab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
- Conditions
- Colon cancer
- Registration Number
- JPRN-jRCT2080220307
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
- >= 18 years of age, adult patients
- documented colon carcinoma
- not a candidate for (neo) adjuvant radiotherapy
- curative surgery not less than 4 and not more than 8 weeks prior to study randomization.
Exclusion criteria:
- evidence of metastatic disease
- previous anti-angiogenic treatment for any malignancy
-previous cytotoxic chemotherapy, radiotherapy, or immunotherapy for colon cancer
- pregnant or lactating women
- fertile men, or women of childbearing potential, not using adequate contraception
- major surgical procedures, open biopsy, or significant traumatic injury, within 28 days prior to study treatment start
- current or recent treatment (within 28 days prior to randomization) with another investigational drug, or participation in another investigational study
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease -free survival,
- Secondary Outcome Measures
Name Time Method